Rovi Pharmaceutical Company estimates that production of Moderna’s vaccine at its facilities in Granada will manufacture about 100 million doses per year, as planned. In an interview with the Efe agency, the vice president and financial director of Rovi, Javier-López Belmonte, has indicated that the American vaccine works with RNA technology, what he considers the present and future of pharmaceutical companies.
Collaboration with Moderna
The manufacture of Moderna’s vaccines will be carried out carried out in a new industrial investment in the facilities of the Rovi Group in Granada. “We are currently adapting our facilities to be in a position to start manufacturing the active ingredient in the third quarter of 2021”, Has pointed out the vice president of Rovi laboratories.
On the other hand, López-Belmonte has pointed out that the collaboration between Rovi and Moderna is “for several years” and that he hopes that the American company will become its “long-term” manufacturing partner: “We hope to be able to help Moderna in the future not only to manufacture their vaccine against Covid-19 but also other products that they have in their pipeline (range under development) “.
New facilities
Rovi expects that its new facilities, which are being built in the municipality of Escúzar, will be fully operational in 2023, once the validation and regulatory processes that will be carried out in the first half of 2022 have been passed. These facilities are designed to double their manufacturing capacity for the active ingredient of low molecular weight heparins, bemiparin and enoxaparin biosimilar.
“Fortunately, we can say that its construction progresses at a good pace and that the pandemic has not caused delays in the schedule that we had set for this new Escúzar plant“, said the vice president of Rovi.
–
